Vanda Pharmaceuticals Stock Analysis
VNDA Stock | USD 5.09 0.15 3.04% |
Vanda Pharmaceuticals is fairly valued with Real Value of 5.21 and Target Price of 5.4. The main objective of Vanda Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Vanda Pharmaceuticals is worth, separate from its market price. There are two main types of Vanda Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Vanda Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Vanda Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Vanda |
Vanda Stock Analysis Notes
About 77.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.55. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vanda Pharmaceuticals recorded a loss per share of 0.19. The entity had not issued any dividends in recent years. Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Vanda Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 278 people. For more information please call the company at 202 734 3400 or visit https://www.vandapharma.com.Vanda Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vanda Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vanda Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Vanda Pharmaceuticals generated a negative expected return over the last 90 days | |
Vanda Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
Vanda Pharmaceuticals has a strong financial position based on the latest SEC filings | |
Over 77.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from thelincolnianonline.com: Stephen Ray Mitchell Sells 5,000 Shares of Vanda Pharmaceuticals Inc. Stock |
Vanda Pharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vanda Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
14th of February 2024 Upcoming Quarterly Report | View | |
1st of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
14th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Vanda Largest EPS Surprises
Earnings surprises can significantly impact Vanda Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2020-10-28 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2017-05-02 | 2017-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2015-11-03 | 2015-09-30 | -0.2 | -0.22 | -0.02 | 10 |
Vanda Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Vanda Pharmaceuticals' ESG score is a quantitative measure that evaluates Vanda Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Vanda Pharmaceuticals' operations that may have significant financial implications and affect Vanda Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Vanda Pharmaceuticals Thematic Classifications
In addition to having Vanda Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Vanda Stock Institutional Investors
Shares | Prudential Financial Inc | 2024-09-30 | 776.8 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 725.4 K | Federated Hermes Inc | 2024-09-30 | 716.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 596.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 559.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 526.8 K | Northern Trust Corp | 2024-09-30 | 501.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 419.5 K | Krensavage Asset Management, Llc | 2024-09-30 | 414.7 K | Blackrock Inc | 2024-06-30 | 8.1 M | Renaissance Technologies Corp | 2024-09-30 | 4 M |
Vanda Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 314.86 M.Vanda Profitablity
The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.23) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.23.Last Reported | Projected for Next Year | ||
Return On Capital Employed | (0.02) | (0.03) |
Management Efficiency
Vanda Pharmaceuticals has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0302) %, meaning that it created substantial loss on money invested by shareholders. Vanda Pharmaceuticals' management efficiency ratios could be used to measure how well Vanda Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Vanda Pharmaceuticals' Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0, whereas Return On Capital Employed is forecasted to decline to (0.03). At present, Vanda Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 226.3 M, whereas Other Current Assets are forecasted to decline to about 7.5 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 9.50 | 9.97 | |
Tangible Book Value Per Share | 7.38 | 7.75 | |
Enterprise Value Over EBITDA | (10.58) | (11.11) | |
Price Book Value Ratio | 0.44 | 0.42 | |
Enterprise Value Multiple | (10.58) | (11.11) | |
Price Fair Value | 0.44 | 0.42 | |
Enterprise Value | 115.7 M | 109.9 M |
Management at Vanda Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Operating Margin (0.23) | Profit Margin (0.09) | Beta 0.767 | Return On Assets (0.04) | Return On Equity (0.03) |
Technical Drivers
As of the 25th of November, Vanda Pharmaceuticals has the insignificant Risk Adjusted Performance, variance of 6.83, and Coefficient Of Variation of (9,437). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vanda Pharmaceuticals, as well as the relationship between them.Vanda Pharmaceuticals Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Vanda Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Vanda Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Vanda Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vanda Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vanda Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vanda Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vanda Pharmaceuticals Outstanding Bonds
Vanda Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vanda Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vanda bonds can be classified according to their maturity, which is the date when Vanda Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Vanda Pharmaceuticals Predictive Daily Indicators
Vanda Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vanda Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Vanda Pharmaceuticals Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 15th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 3rd of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 19th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 8th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 1st of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Vanda Pharmaceuticals Forecast Models
Vanda Pharmaceuticals' time-series forecasting models are one of many Vanda Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vanda Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Vanda Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Vanda Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vanda shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vanda Pharmaceuticals. By using and applying Vanda Stock analysis, traders can create a robust methodology for identifying Vanda entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.03 | 0.03 | |
Operating Profit Margin | (0.07) | (0.08) | |
Net Profit Margin | 0.01 | 0.01 | |
Gross Profit Margin | 0.92 | 0.69 |
Current Vanda Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vanda analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vanda analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
5.4 | Buy | 4 | Odds |
Most Vanda analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Vanda stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Vanda Pharmaceuticals, talking to its executives and customers, or listening to Vanda conference calls.
Vanda Stock Analysis Indicators
Vanda Pharmaceuticals stock analysis indicators help investors evaluate how Vanda Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vanda Pharmaceuticals shares will generate the highest return on investment. By understating and applying Vanda Pharmaceuticals stock analysis, traders can identify Vanda Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 135.5 M | |
Common Stock Shares Outstanding | 57.6 M | |
Total Stockholder Equity | 544.9 M | |
Tax Provision | 5.8 M | |
Quarterly Earnings Growth Y O Y | -0.959 | |
Property Plant And Equipment Net | 9.1 M | |
Cash And Short Term Investments | 388.3 M | |
Cash | 135.8 M | |
Accounts Payable | 7.1 M | |
Net Debt | -126.4 M | |
50 Day M A | 4.797 | |
Total Current Liabilities | 87.7 M | |
Other Operating Expenses | 206.6 M | |
Non Current Assets Total | 215.5 M | |
Forward Price Earnings | 30.303 | |
Non Currrent Assets Other | 10 M | |
Stock Based Compensation | 14 M |
Complementary Tools for Vanda Stock analysis
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |